tetano
Editor, Senior Moderator
Expert Opin Drug Saf
. 2020 Nov 12.
doi: 10.1080/14740338.2021.1850690. Online ahead of print.
Association between oseltamivir use and neuropsychiatric adverse events in influenza patients: a nationwide population-based cohort study
Hye-Rim Kang[SUP] 1 [/SUP], Suk-Chan Jang[SUP] 1 [/SUP], Ju-Young Shin[SUP] 1 [/SUP]
Affiliations
Abstract
Background: A potential risk of neuropsychiatric adverse events (NPAEs) in patients with oseltamivir use has remained controversial by retrospective cohort studies. This nationwide population-based cohort study aimed to assess the risk of NPAEs in influenza patients undergoing oseltamivir treatment (users) compared with a propensity score-matched cohort of patients not receiving oseltamivir (non-users). Research design and methods: Using the Korean National Health Service-Sample Cohort Database, patients diagnosed with incident influenza during 2003-2013 were divided into two cohorts: oseltamivir users and non-users. We calculated adjusted hazard ratios (aHRs) for the 5-day treatment course with oseltamivir using Cox regression analysis. Results: The incidence rate of NPAEs during 5-day oseltamivir treatment was 0.0029 and 0.0023 in oseltamivir users and non-users, respectively. The risk of NPAEs was different according to age, with an increased risk in patients aged 10-19 years (aHR 2.69, 95% CI 1.05-6.93) and a decreased risk in patients aged 0-9 years (aHR 0.46, 95% CI 0.24-0.88). The non-significant positive associations were observed in patients aged 20-64 years and those aged greater than 65 years. Conclusions: Although the reason for the inverse association in children aged 0-9 years is unknown, oseltamivir could increase the risk of NPAEs for children or adolescents aged greater than 10 years.
Keywords: influenza; neuropsychiatric adverse events; oseltamivir; pharmacoepidemiology study.
. 2020 Nov 12.
doi: 10.1080/14740338.2021.1850690. Online ahead of print.
Association between oseltamivir use and neuropsychiatric adverse events in influenza patients: a nationwide population-based cohort study
Hye-Rim Kang[SUP] 1 [/SUP], Suk-Chan Jang[SUP] 1 [/SUP], Ju-Young Shin[SUP] 1 [/SUP]
Affiliations
- PMID: 33183123
- DOI: 10.1080/14740338.2021.1850690
Abstract
Background: A potential risk of neuropsychiatric adverse events (NPAEs) in patients with oseltamivir use has remained controversial by retrospective cohort studies. This nationwide population-based cohort study aimed to assess the risk of NPAEs in influenza patients undergoing oseltamivir treatment (users) compared with a propensity score-matched cohort of patients not receiving oseltamivir (non-users). Research design and methods: Using the Korean National Health Service-Sample Cohort Database, patients diagnosed with incident influenza during 2003-2013 were divided into two cohorts: oseltamivir users and non-users. We calculated adjusted hazard ratios (aHRs) for the 5-day treatment course with oseltamivir using Cox regression analysis. Results: The incidence rate of NPAEs during 5-day oseltamivir treatment was 0.0029 and 0.0023 in oseltamivir users and non-users, respectively. The risk of NPAEs was different according to age, with an increased risk in patients aged 10-19 years (aHR 2.69, 95% CI 1.05-6.93) and a decreased risk in patients aged 0-9 years (aHR 0.46, 95% CI 0.24-0.88). The non-significant positive associations were observed in patients aged 20-64 years and those aged greater than 65 years. Conclusions: Although the reason for the inverse association in children aged 0-9 years is unknown, oseltamivir could increase the risk of NPAEs for children or adolescents aged greater than 10 years.
Keywords: influenza; neuropsychiatric adverse events; oseltamivir; pharmacoepidemiology study.